Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01577758 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C
A Phase 1 study of Advanced Gastrointestinal Malignancies, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT01577758 is a Phase 1 study of Advanced Gastrointestinal Malignancies that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 41 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01577758, a Phase 1 study of Advanced Gastrointestinal Malignancies, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an Open-Label, Multicenter, Dose Escalation, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C.
Conditions Studied
Interventions
- DRUG MLN0264
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01577758
The ClinicalTrials.gov registry entry for NCT01577758 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Gastrointestinal Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MLN0264 is the first listed.
NCT01577758 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01577758 about?
NCT01577758 is a clinical study titled "Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C". This is an Open-Label, Multicenter, Dose Escalation, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C.
What is the current status of trial NCT01577758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2012-06. Estimated completion is 2014-02.
What conditions does trial NCT01577758 study?
This clinical trial studies the following conditions: Advanced Gastrointestinal Malignancies.
What interventions are being tested in trial NCT01577758?
The interventions under investigation include: MLN0264 (DRUG).
Who is sponsoring clinical trial NCT01577758?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01577758 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.